Incretin mimetics , also known as GLP-1 receptor agonists , are medications that mimic the action of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone
The SGLT2 inhibitor confusion SGLT2 inhibitors are a class of diabetes medications that includes empagliflozin, dapagliflozin, and canagliflozin
Semaglutide is mainly an anti-diabetic and secondarily an anti-obesity medication
It is found in virtually every cell of the human body, acting as a primary line of defense against oxidative stress
Therefore, inhibiting CAR8 could be a promising strategy for improving GLP-1 secretion, a new approach to treating diabetes [143]
Like other peptides in this class, the dose is titrated upward gradually starting low and stepping up every four weeks to allow the body to adapt and minimise gastrointestinal side effects